Skip to main content

Table 1 Correlation between SRSF9 expression and the clinicopathological features in 63 CRC patients

From: SRSF9 promotes colorectal cancer progression via stabilizing DSN1 mRNA in an m6A-related manner

Features SRSF9 expression χ2 P value*
Low (n, %) High (n, %)
Cases 44 19   
Gender
 Male 25 (65.8) 13 (34.2) 0.746 0.418
 Female 19 (76) 6 (24)   
Age (year)
 > 45 40 (72.7) 15 (27.3) 1.713 0.229
 ≤ 45 4 (50) 4 (50)
Tumor size (cm)
 > 5 14 (73.7) 5 (26.3) 0.191 0.770
 ≤ 5 30 (68.2) 14 (31.8)
Grade of differentiation
 Low 6 (85.7) 1 (14.3) 2.270 0.321
 Medium 23 (59) 16 (41)
 High 15 (88.2) 2 (11.8)
Position
 Colon 31 (66) 16 (34) 1.325 0.350
 Rectum 13 (81.3) 3 (18.7)
Perineural invasion
 Yes 9 (69.2) 4 (30.8) 0.003 1.000
 No 35 (70) 15 (30)
Cancer nodules
 Yes 11 (68.8) 5 (31.2) 0.012 1.000
 No 33 (70.2) 14 (29.8)
Tumor depth
T1–T2 2 (100) 0 (0) 2.527 0.283
T3–T4 42 (68.9) 19 (31.1)
Lymph node metastasis
 Positive 19 (57.6) 14 (42.4) 4.950 0.031*
 Negative 25 (83.3) 5 (16.7)
Dukes stage
 Stage A–B 25 (89.3) 3 (10.7) 9.204 0.027*
 Stage C–D 19 (54.3) 16 (45.7)
  1. *Chi-square test *p < 0.05